ZBIO
Zenas BioPharma, Inc. Common Stock
stockNASDAQ
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the NASDAQ Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of the Nasdaq Stock Market listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 27.55 | 2026-09-28 | +2.98% | 2.701 |
| 1M | 32.88 | 2026-09-04 | -13.72% | 1.595 |
| 3M | 26.45 | 2026-07-06 | +7.26% | 0.671 |
| 6M | 22.26 | 2026-04-06 | +27.45% | 0.441 |
| 1Y | 23.03 | 2025-10-06 | +23.19% | 0.857 |
| 2Y | 18.81 | 2024-10-04 | +50.82% | — |
| 5Y | 10.02 | 2020-03-27 | +183.12% | 1.285 |
Zenas BioPharma, Inc. Common Stock (NASDAQ:ZBIO) stock price today is $28.37, and today's volume is 1,513,617. ZBIO is up 1.539% today. The 30 day average volume is 685,748. ZBIO market cap is $1.85B with 65.18M shares outstanding.